中国老年甲状腺疾病诊治专家共识(2021)

中国老年协会内分泌代谢病学组 Aging Med (Milton) . 2021 Jul 2;4(2):70-92

为提高我国老年甲状腺疾病诊治水平,促进健康老龄化,中国老年医学会内分泌代谢疾病组、中国内分泌学会甲状腺学组联合起草了《中国老年甲状腺疾病诊断与治疗专家共识》。中国老年人甲状腺疾病治疗”(简

中文标题:

中国老年甲状腺疾病诊治专家共识(2021)

发布日期:

简要介绍:

为提高我国老年甲状腺疾病诊治水平,促进健康老龄化,中国老年医学会内分泌代谢疾病组、中国内分泌学会甲状腺学组联合起草了《中国老年甲状腺疾病诊断与治疗专家共识》。中国老年人甲状腺疾病治疗”(简称共识)。共识由五个部分组成,就主要临床问题提出了 40 条建议。共识强调临床关注老年人下丘脑-垂体-甲状腺轴的年龄相关变化,建议应用老年综合评估,全面评估甲状腺疾病及相关干预对整体健康状况的影响。同时,建议在入院或入院期间普遍开展甲状腺功能减退症筛查和常规健康检查。此外,针对老年人的甲亢、甲减、甲状腺结节和分化型甲状腺癌,制定了个体化分层管理,包括治疗方案、控制范围和诊治流程图。该共识将为老年病学家、内分泌学家和全科医生对老年人甲状腺疾病的临床决策和健康管理提供依据。

相关资料下载:
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=49d0c1c00213184d, title=中国老年甲状腺疾病诊治专家共识(2021) , enTitle=, guiderFrom=Aging Med (Milton) . 2021 Jul 2;4(2):70-92, authorId=0, author=, summary=为提高我国老年甲状腺疾病诊治水平,促进健康老龄化,中国老年医学会内分泌代谢疾病组、中国内分泌学会甲状腺学组联合起草了《中国老年甲状腺疾病诊断与治疗专家共识》。中国老年人甲状腺疾病治疗”(简, cover=, journalId=0, articlesId=null, associationId=1943, associationName=中国老年协会内分泌代谢病学组, associationIntro=Endocrine Metabolic Diseases Group of the Chinese Geriatrics Society, copyright=0, guiderPublishedTime=null, originalUrl=, linkOutUrl=, content=<p>为提高我国老年甲状腺疾病诊治水平,促进健康老龄化,中国老年医学会内分泌代谢疾病组、中国内分泌学会甲状腺学组联合起草了《中国老年甲状腺疾病诊断与治疗专家共识》。中国老年人甲状腺疾病治疗&rdquo;(简称共识)。共识由五个部分组成,就主要临床问题提出了 40 条建议。共识强调临床关注老年人下丘脑-垂体-甲状腺轴的年龄相关变化,建议应用老年综合评估,全面评估甲状腺疾病及相关干预对整体健康状况的影响。同时,建议在入院或入院期间普遍开展甲状腺功能减退症筛查和常规健康检查。此外,针对老年人的甲亢、甲减、甲状腺结节和分化型甲状腺癌,制定了个体化分层管理,包括治疗方案、控制范围和诊治流程图。该共识将为老年病学家、内分泌学家和全科医生对老年人甲状腺疾病的临床决策和健康管理提供依据。</p>, tagList=[TagDto(tagId=3313, tagName=甲状腺疾病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=19, categoryName=老年医学, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8000, appHits=648, showAppHits=0, pcHits=750, showPcHits=7351, likes=1, shares=76, comments=29, approvalStatus=1, publishedTime=Fri Jul 16 20:29:19 CST 2021, publishedTimeString=null, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Fri Jul 16 20:29:07 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Thu Jan 04 16:19:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击:
评论区 (24)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1204232, encodeId=b2b3120423215, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f695640945, createdName=ms1000001674182102, createdTime=Sun Mar 20 06:12:23 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191871, encodeId=086f11918e103, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cf02947578, createdName=retsingya, createdTime=Thu Feb 10 16:08:19 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190371, encodeId=c3c511903e193, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8795679309, createdName=123dk1, createdTime=Sat Feb 05 20:24:45 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187058, encodeId=7326118e058bc, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:11:36 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187057, encodeId=e456118e0575f, content=学习了这个专家共识,对老年甲状腺疾病诊疗有了规范的指导,很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:10:54 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-03-20 ms1000001674182102

    感谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1204232, encodeId=b2b3120423215, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f695640945, createdName=ms1000001674182102, createdTime=Sun Mar 20 06:12:23 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191871, encodeId=086f11918e103, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cf02947578, createdName=retsingya, createdTime=Thu Feb 10 16:08:19 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190371, encodeId=c3c511903e193, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8795679309, createdName=123dk1, createdTime=Sat Feb 05 20:24:45 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187058, encodeId=7326118e058bc, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:11:36 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187057, encodeId=e456118e0575f, content=学习了这个专家共识,对老年甲状腺疾病诊疗有了规范的指导,很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:10:54 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-02-10 retsingya

    很有收获

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1204232, encodeId=b2b3120423215, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f695640945, createdName=ms1000001674182102, createdTime=Sun Mar 20 06:12:23 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191871, encodeId=086f11918e103, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cf02947578, createdName=retsingya, createdTime=Thu Feb 10 16:08:19 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190371, encodeId=c3c511903e193, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8795679309, createdName=123dk1, createdTime=Sat Feb 05 20:24:45 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187058, encodeId=7326118e058bc, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:11:36 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187057, encodeId=e456118e0575f, content=学习了这个专家共识,对老年甲状腺疾病诊疗有了规范的指导,很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:10:54 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-02-05 123dk1

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1204232, encodeId=b2b3120423215, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f695640945, createdName=ms1000001674182102, createdTime=Sun Mar 20 06:12:23 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191871, encodeId=086f11918e103, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cf02947578, createdName=retsingya, createdTime=Thu Feb 10 16:08:19 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190371, encodeId=c3c511903e193, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8795679309, createdName=123dk1, createdTime=Sat Feb 05 20:24:45 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187058, encodeId=7326118e058bc, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:11:36 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187057, encodeId=e456118e0575f, content=学习了这个专家共识,对老年甲状腺疾病诊疗有了规范的指导,很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:10:54 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-22 121304f3m09暂无昵称

    很有收获

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1204232, encodeId=b2b3120423215, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f695640945, createdName=ms1000001674182102, createdTime=Sun Mar 20 06:12:23 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191871, encodeId=086f11918e103, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cf02947578, createdName=retsingya, createdTime=Thu Feb 10 16:08:19 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190371, encodeId=c3c511903e193, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8795679309, createdName=123dk1, createdTime=Sat Feb 05 20:24:45 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187058, encodeId=7326118e058bc, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:11:36 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187057, encodeId=e456118e0575f, content=学习了这个专家共识,对老年甲状腺疾病诊疗有了规范的指导,很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b1a2235083, createdName=121304f3m09暂无昵称, createdTime=Sat Jan 22 06:10:54 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-22 121304f3m09暂无昵称

    学习了这个专家共识,对老年甲状腺疾病诊疗有了规范的指导,很有收获

    0